Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 125

1.

DNA metalating-intercalating hybrid agents for the treatment of chemoresistant cancers.

Suryadi J, Bierbach U.

Chemistry. 2012 Oct 8;18(41):12926-34. doi: 10.1002/chem.201202050. Epub 2012 Sep 17.

PMID:
22987397
2.
3.

Synthesis, biological activity, and DNA-damage profile of platinum-threading intercalator conjugates designed to target adenine.

Guddneppanavar R, Saluta G, Kucera GL, Bierbach U.

J Med Chem. 2006 Jun 1;49(11):3204-14.

PMID:
16722638
4.
6.

Replacement of a thiourea with an amidine group in a monofunctional platinum-acridine antitumor agent. Effect on DNA interactions, DNA adduct recognition and repair.

Kostrhunova H, Malina J, Pickard AJ, Stepankova J, Vojtiskova M, Kasparkova J, Muchova T, Rohlfing ML, Bierbach U, Brabec V.

Mol Pharm. 2011 Oct 3;8(5):1941-54. doi: 10.1021/mp200309x. Epub 2011 Aug 17.

7.
8.

Adenine-N3 in the DNA minor groove - an emerging target for platinum containing anticancer pharmacophores.

Guddneppanavar R, Bierbach U.

Anticancer Agents Med Chem. 2007 Jan;7(1):125-38. Review.

PMID:
17266509
9.

PT-ACRAMTU, a platinum-acridine anticancer agent, lengthens and aggregates, but does not stiffen or soften DNA.

Dutta S, Snyder MJ, Rosile D, Binz KL, Roll EH, Suryadi J, Bierbach U, Guthold M.

Cell Biochem Biophys. 2013;67(3):1103-13. doi: 10.1007/s12013-013-9614-8.

10.

Rates of intercalator-driven platination of DNA determined by a restriction enzyme cleavage inhibition assay.

Choudhury JR, Rao L, Bierbach U.

J Biol Inorg Chem. 2011 Mar;16(3):373-80. doi: 10.1007/s00775-010-0733-z. Epub 2010 Nov 18.

11.

Characterization of the bisintercalative DNA binding mode of a bifunctional platinum-acridine agent.

Choudhury JR, Bierbach U.

Nucleic Acids Res. 2005 Sep 28;33(17):5622-32. Print 2005.

12.

A non-cross-linking platinum-acridine agent with potent activity in non-small-cell lung cancer.

Ma Z, Choudhury JR, Wright MW, Day CS, Saluta G, Kucera GL, Bierbach U.

J Med Chem. 2008 Dec 11;51(23):7574-80. doi: 10.1021/jm800900g.

13.
14.
15.

Redesigning the DNA-targeted chromophore in platinum-acridine anticancer agents: a structure-activity relationship study.

Pickard AJ, Liu F, Bartenstein TF, Haines LG, Levine KE, Kucera GL, Bierbach U.

Chemistry. 2014 Dec 1;20(49):16174-87. doi: 10.1002/chem.201404845. Epub 2014 Oct 10.

16.

Effect of the diamine nonleaving group in platinum-acridinylthiourea conjugates on DNA damage and cytotoxicity.

Guddneppanavar R, Choudhury JR, Kheradi AR, Steen BD, Saluta G, Kucera GL, Day CS, Bierbach U.

J Med Chem. 2007 May 3;50(9):2259-63. Epub 2007 Apr 5.

PMID:
17408248
17.

Probing platinum-adenine-n3 adduct formation with DNA minor-groove binding agents.

Rao L, West TK, Saluta G, Kucera GL, Bierbach U.

Chem Res Toxicol. 2010 Jul 19;23(7):1148-50. doi: 10.1021/tx100170p.

18.

Design, synthesis, and biological activity of a novel non-cisplatin-type platinum-acridine pharmacophore.

Martins ET, Baruah H, Kramarczyk J, Saluta G, Day CS, Kucera GL, Bierbach U.

J Med Chem. 2001 Dec 6;44(25):4492-6.

PMID:
11728195
19.

Analysis of the DNA damage produced by a platinum-acridine antitumor agent and its effects in NCI-H460 lung cancer cells.

Qiao X, Zeitany AE, Wright MW, Essader AS, Levine KE, Kucera GL, Bierbach U.

Metallomics. 2012 Jul;4(7):645-52. doi: 10.1039/c2mt20031g. Epub 2012 Mar 29.

Supplemental Content

Support Center